IP Library Granted Patent US 9,289,442
Granted Patent B2
US 9,289,442 · App. 14/134,737 · Granted Mar 22, 2016

Topical compositions

Inventors: Ryan Doxey (Raleigh, NC); Nathan Stasko (Durham, NC)
Assignee: Novan, Inc.
A61K31/695A61K9/0014A61K47/10A61K47/20A61K47/34A61K47/38A61K9/143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,289,442
App. No.
14/134,737
Granted
Mar 22, 2016
Kind
B2
Abstract

Provided herein are anhydrous compositions that include at least one viscosity increasing agent, at least one organic solvent and at least one humectant. Such compositions may also include at least one active pharmaceutical ingredient (API) and/or at least one water repellant. Related compositions, methods and kits are also provided.

Claims (12)

1. An anhydrous topical pharmaceutical composition comprising:

hydroxypropyl cellulose present in the composition at a concentration in a range of 0.1% to 15% by weight of the anhydrous topical pharmaceutical composition;

ethyl alcohol or isopropyl alcohol present in the composition at a concentration in a range of 45% to 95% by weight of the anhydrous topical pharmaceutical composition;

hexylene glycol present in the composition at a concentration in a range of 1% to 20% by weight of the anhydrous topical pharmaceutical composition;

cyclomethicone present in the composition at a concentration in a range of 0.5% to 15% by weight of the anhydrous topical pharmaceutical composition; and

a diazeniumdiolated co-condensed silica particle at a concentration in a range of 0.1% to 40% by weight of the anhydrous topical pharmaceutical composition.

2. The anhydrous topical pharmaceutical composition of claim 1 , wherein the diazeniumdiolated co-condensed silica particle has a mean particle size of less than 10 μm.

3. The anhydrous topical pharmaceutical composition of claim 1 , wherein the composition is packaged and the packaged composition has a shelf life of at least four weeks.

4. The anhydrous topical pharmaceutical composition of claim 3 , wherein the shelf life is under refrigerated conditions.

5. The anhydrous topical pharmaceutical composition of claim 3 , wherein the shelf life is at least 52 weeks.

6. A method of treating a dermatological condition comprising applying the anhydrous topical pharmaceutical composition of claim 1 to the skin of a patient to treat the dermatological condition.

7. The method of claim 6 , wherein the dermatological condition comprises acne.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2025
From: LNHC, INC.
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 071481/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2024
From: NOVAN, INC.
To: LNHC, INC.
Reel/Frame 066350/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2016
From: DOXEY, RYAN; STASKO, NATHAN
To: NOVAN, INC.
Reel/Frame 037436/0321 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2014
From: DOXEY, RYAN; STASKO, NATHAN
To: NOVAN, INC.
Reel/Frame 031972/0525 →
Continuity (4)
Continuation PCTUS2012045384 · Jul 3, 2012
Provisional Application 61504628 · Jul 5, 2011
Provisional Application 61610137 · Mar 13, 2012
Related Publication 20140105986A1 · Apr 17, 2014